COMPASS Pathways plc (NASDAQ:CMPS) Major Shareholder Life Sciences N.V. Atai Sells 2,660,000 Shares

COMPASS Pathways plc (NASDAQ:CMPS) major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the company’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $6.05, for a total value of $16,093,000.00. Following the sale, the insider now owns 6,905,774 shares of the company’s stock, valued at $41,779,932.70. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

COMPASS Pathways Stock Performance

NASDAQ:CMPS opened at $6.81 on Monday. The company has a debt-to-equity ratio of 0.13, a current ratio of 12.03 and a quick ratio of 12.03. The firm has a 50-day moving average of $7.16 and a two-hundred day moving average of $7.61. The stock has a market cap of $465.67 million, a P/E ratio of -2.87 and a beta of 2.27. COMPASS Pathways plc has a 1-year low of $5.01 and a 1-year high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.03). During the same quarter in the prior year, the firm earned ($0.62) EPS. On average, research analysts expect that COMPASS Pathways plc will post -2.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On COMPASS Pathways

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quest Partners LLC purchased a new position in COMPASS Pathways in the 4th quarter valued at about $33,000. Blue Trust Inc. bought a new position in shares of COMPASS Pathways during the second quarter worth about $81,000. Kennedy Capital Management LLC bought a new position in shares of COMPASS Pathways during the first quarter worth about $139,000. Tidal Investments LLC lifted its position in shares of COMPASS Pathways by 43.6% during the first quarter. Tidal Investments LLC now owns 19,082 shares of the company’s stock worth $159,000 after purchasing an additional 5,795 shares during the last quarter. Finally, Fore Capital LLC bought a new position in shares of COMPASS Pathways during the second quarter worth about $181,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a report on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and set a $120.00 price target on shares of COMPASS Pathways in a research report on Friday, August 23rd. Canaccord Genuity Group decreased their price target on shares of COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating for the company in a research report on Friday, August 2nd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $23.00 price target on shares of COMPASS Pathways in a research report on Tuesday, September 10th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $47.40.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.